[go: up one dir, main page]

WO2005117926A1 - Agent pour améliorer la flore intestinale bactérienne - Google Patents

Agent pour améliorer la flore intestinale bactérienne Download PDF

Info

Publication number
WO2005117926A1
WO2005117926A1 PCT/JP2005/004742 JP2005004742W WO2005117926A1 WO 2005117926 A1 WO2005117926 A1 WO 2005117926A1 JP 2005004742 W JP2005004742 W JP 2005004742W WO 2005117926 A1 WO2005117926 A1 WO 2005117926A1
Authority
WO
WIPO (PCT)
Prior art keywords
bacteria
pine bark
pine
food
intestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2005/004742
Other languages
English (en)
Japanese (ja)
Inventor
Kinya Takagaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyo Shinyaku Co Ltd
Original Assignee
Toyo Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyo Shinyaku Co Ltd filed Critical Toyo Shinyaku Co Ltd
Publication of WO2005117926A1 publication Critical patent/WO2005117926A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to an intestinal flora improving agent comprising a pine bark extract as an active ingredient.
  • the present invention has been made in view of the above problems, and an object thereof is to provide an intestinal flora improving agent capable of obtaining a stable effect for improving the intestinal environment.
  • the present inventors have conducted intensive research. As a result, it was found that the pine husk extract increases useful bacteria that inhabit the intestine and improves the intestinal environment, thereby completing the present invention.
  • the intestinal flora improving agent of the present invention is characterized by comprising a pine bark extract as an active ingredient.
  • the present invention also relates to a food containing a pine bark extract and at least one selected from the group consisting of oligosaccharides, bifidobacteria and lactic acid bacteria.
  • the agent for improving intestinal flora of the present invention increases useful bacteria (for example, Bifidobacterium adrecens, Bacillus coagulans, etc.).
  • useful bacteria for example, Bifidobacterium adrecens, Bacillus coagulans, etc.
  • the intestinal flora-improving agent of the present invention can obtain a stable effect for improving the intestinal environment.
  • pine bark extract First, the pine bark extract used in the present invention will be described.
  • the pine bark used as the raw material of the extract includes, for example, French coast pine (Pinus Ma rtima), larch, black pine, ripe pine, Japanese pine, goyo pine Bark of plants belonging to the order of pine, Pinus pine, Pinus pine, Ryukyu pine, Luc pine, Dio pine, White pine, Aneda in Quebec, Canada.
  • French coast pine Pieris Ma rtima
  • larch black pine
  • ripe pine Japanese pine
  • Pinus pine, Pinus pine, Ryukyu pine, Luc pine, Dio pine, White pine, Aneda in Quebec, Canada it is preferable to obtain an extract from the bark of French coastal pine (Pinus Martima).
  • French coastal pine is a marine pine that grows on the Atlantic coast of southern France.
  • This French coastal pine bark is composed of polyanthocyanin, including proanthocyanidins, which are condensed tannins with a degree of polymerization of 2 or more, consisting of flavan 1-ol and Z or flavan 1 3,4-diol. It contains physiologically active ingredients such as phenols, organic acids, and sugars. In particular, it contains abundant proanthocyanidins of condensation polymers (2 to 4 mer) having a degree of polymerization of 2 to 4.
  • a polymer having a degree of polymerization of 2 to 4 and comprising flavan 1-all opi or flavan 1 3,4-diol as a constituent unit is represented by OPC Oligomeric 'proanthocyanidins; o 1 lg ome ricproanthocyanidin) and when.
  • OPC is an antioxidant and is said to reduce the risk of adult diseases such as cancer and heart disease. OPC also has the effect of improving allergic conditions such as arthritis, atopic dermatitis and hay fever, and inhibiting the oxidation and degradation of collagen.
  • OPC has the effect of restoring blood vessel strength and elasticity; the effect of reducing blood cholesterol and LDL; the effect of reducing blood pressure against hypertension; and the prevention of cholesterol adhesion Effect of regenerating vitamin E decomposed by active oxygen; enhancement of vitamin E It is known to have an effect as an agent.
  • a pine bark extract containing 20% by mass or more of OPC is preferably used. More preferably, it is 30% by mass or more.
  • the content of proanthocyanidins in the bark extract is not particularly limited, but if the content of proanthocyanidins in the bark extract is high, the physiological activity of proanthocyanidins itself is reduced. Therefore, the content of proanthocyanidin in the extract is preferably less than 95% by mass, and preferably less than 90% by mass.
  • the pine bark extract is obtained using the above pine bark and a solvent.
  • the solvent herein include organic solvents, water, and polar solvents.
  • water is used for extraction, it is preferable to use warm water or hot water.
  • a salt such as sodium chloride to these waters.
  • organic solvents that are acceptable for the production of foods or pharmaceuticals are used, for example, methanol, ethanol, 1 propanol, 2 1-propanol, 1-butanol, 2-butanol, acetone. , Hexane, Cyclohexane, Propylene glycol, Hydrous ethanol, Hydrous propylene glycol, Ethyl methyl ketone, Glycerin, Methyl acetate, Ethyl acetate, Jetyl ether, Dichloromethane, Edible oils and fats, 1, 1, 1, 2-Tetrafluoroethane , And 1, 1,2-trichloroethene.
  • the above solvents may be used alone or in combination.
  • water, hot water, and polar solvents such as ethanol and propylene dalycol are preferably used.
  • a mixed solvent of water and a polar solvent such as hydrous ethanol and hydrous propylene glycol is preferably used.
  • the method for extracting proanthocyanidins from pine bark is not particularly limited, For example, a warm extraction method or a supercritical fluid extraction method is used.
  • Supercritical fluid extraction is a method that uses a supercritical fluid, which is a fluid that exceeds the critical point (critical temperature, critical pressure) of a substance's gas-liquid.
  • a supercritical fluid which is a fluid that exceeds the critical point (critical temperature, critical pressure) of a substance's gas-liquid.
  • the supercritical fluid carbon dioxide, ethylene, propane, nitrous oxide (laughing gas) and the like are used, and carbon dioxide is preferably used.
  • the supercritical fluid extraction method includes an extraction process for extracting a target component with a supercritical fluid and a separation process for separating the target component and the supercritical fluid.
  • a separation process for separating the target component and the supercritical fluid.
  • either extraction separation due to pressure change, extraction separation due to temperature change, or extraction separation using an adsorbent or absorbent may be performed.
  • supercritical fluid extraction may be performed by an entrainer addition method.
  • ethanol, propanol, n-hexane, acetone, toluene, other aliphatic lower alcohols, aliphatic hydrocarbons, aromatic hydrocarbons, or ketones are added to the supercritical fluid.
  • Addition of ⁇ 2 O WZV% and perform supercritical fluid extraction with the resulting extraction fluid to dramatically increase the solubility of the target extract, such as OPC and catechins (described later), in the extraction fluid It is a method for enhancing the selectivity of separation, and a method for efficiently obtaining a pine husk extract.
  • the supercritical fluid extraction method can be operated at a relatively low temperature, so it can be applied to substances that are altered and decomposed at high temperatures; the advantage that the extraction fluid does not remain; There is an advantage that the solvent process can be omitted and the process becomes simple.
  • Extraction from pine bark may be performed by a method other than the above method, for example, a method such as a liquid carbon dioxide batch method, a liquid carbon dioxide reflux method, or a supercritical carbon dioxide reflux method.
  • a method such as a liquid carbon dioxide batch method, a liquid carbon dioxide reflux method, or a supercritical carbon dioxide reflux method.
  • the pine bark extract containing proanthocyanidin as a main component is specifically prepared by the following method, but this is an example and is not limited to this method.
  • the precipitate is dissolved in 100 ml of ethyl acetate and then added to 1 L of black mouth form again for precipitation, and then a washing step is repeated twice.
  • a washing step is repeated twice.
  • components such as proanthocyanin are extracted from pine bark using ethanol or water, more preferably while heating, and polyphenol It is preferable to purify using a resin (for example, Diaion HP-2O, Sephade X-LH2O, or Amberlite) or an ultrafiltration membrane that exhibits an adsorptive property to. In this way, extraction of pine husk with high content of proanthocyanidins, especially OPC You can get things. (Intestinal flora improving agent)
  • the “intestinal flora improving agent” refers to an agent that increases or activates useful bacteria in the intestine by ingestion.
  • the useful bacteria here are microorganisms that have a beneficial effect on human or animal health.
  • Representative useful bacteria include, for example, bifidobacteria and lactic acid bacteria.
  • Examples of the bifidobacteria include known bacterial strains of the genus Bibidobatterium. Specific examples of bifidobacteria include Bifidobacteri um adolescentis, B. 1 ong um, and B. bifid um. Bifidobacteria resident in the human intestine, regardless of, such as B. pseudolong um, B. the rmo phir um . Examples of lactic acid bacteria include bacteria belonging to the genus Lactobacillus, Enterococcus, and Streptococcus. Specific examples of lactic acid bacteria include Lactobacillus casei, L. acidophilus, L. plantar um, L.
  • Enocerocus fa Examples include E. faeci um, E. hirae, Streptococcusbovis, and Streptococcusther mo phi 1 us.
  • any microorganism that is beneficial to the health of the host may be used.
  • useful bacteria include Bacillus and Clostridium bacteria.
  • Bacillus genus include Bacillus' Toyo (B acillustoyoi), Bacillus' Coagulans, Bacillus subtilis varietas' Nat one (B. subtilis V ar. Natto), Patinoles lichehonoremus (B lichenifo rm is), Bacillus. B. subtilis and so on.
  • Examples of the genus Clostridium include C 1 ostridi urn butyric um.
  • a new agent may be prepared by adding a single or several kinds of useful bacteria to the intestinal flora improving agent of the present invention. Ingestion of such agents will not only increase the useful bacteria that inhabit the intestines, but also the added useful bacteria. As a result, the intestinal flora can be improved, that is, the intestinal environment can be improved.
  • the method for preparing the useful bacteria is not particularly limited. For example, after mass cultivation is performed using a known medium and culture method, a known dispersion medium is added to the cell suspension and freeze-dried. And a method of coating an enteric substance as disclosed in JP-A-4-41434. Among these, when useful bacteria are added, it is preferable to use the useful bacteria coated and the useful bacteria having a high reach to the intestine.
  • Examples of useful bacteria having a high rate of reaching the intestine include sporic lactic acid bacteria such as Bacillus coagulans, bifidobacterum longum, ratatobacillus casei, lactobacillus acidophilus, ratatobacillus hel Examples include veticus, lactobacillus delproiki, streptococcus thermobirath, etc.
  • the intake of the intestinal flora improving agent of the present invention is not particularly limited.
  • the intake of the intestinal flora improving agent may be determined by the daily intake of pine bark extract.
  • the lower limit is preferably 0.001 g or more, preferably 0.02 g or more, and the upper limit is 3 g or less, preferably 1 g or less.
  • the useful bacteria such as lactic acid bacteria and bifidobacteria to the intestinal flora improving agent of the present TsutomuAkira is, kill adult per day, a 1 0 5 to 1 0 1 of the two about the number of bacteria beneficial bacteria in the intake
  • these useful bacteria are preferably viable bacteria.
  • the mixing ratio (mass ratio) of useful bacteria and pine bark extract in the present invention can be mixed at about 99: 1-1 to 1: 999.
  • oligosaccharide for the purpose of enhancing the gut microbiota improving effect of the present invention, it is also possible to add oligosaccharide to the pine bark extract! ,.
  • the oligosaccharide in the present invention include homo-oligosaccharides such as xylooligosaccharide, and hetero-oligosaccharides such as galactosyl sucrose, soybean oligosaccharide, galata oligosaccharide, furata oligosaccharide, lactulose, raffinose and palatinose oligosaccharide.
  • the blending amount of such an oligosaccharide is not particularly limited, but the mixing ratio (mass ratio) of the pine bark extract and the oligosaccharide is preferably about 10: 1 to about I: 300.
  • the intestinal flora improving agent of the present invention may be taken alone or in a food or medicine.
  • the blending ratio is not particularly limited.
  • intestinal flora-improving agent for foods, etc. so that the lower limit of the content of pine bark extract is 0.001% by mass or more, preferably 0.0100% by mass or more. It is good to combine.
  • an intestinal flora-improving agent is preferably added to foods or the like so that the upper limit of the content of the pine bark extract is 50% by mass or less, preferably 20% by mass or less.
  • the intestinal flora-improving agent of the present invention contains the following ingredients as necessary. You may add. Examples of ingredients that may be added include royal jelly, oral police, vitamins (groups A, B, C, D, E, K, folic acid, pantothenic acid, piotin, and derivatives thereof), minerals ( Iron, magnesium, calcium, zinc, etc.), selenium, chitin 'chitosan, lecithin, polyphenols other than proanthocyanidins and catechins contained in pine bark extract (hydrophilic antocyanins, isoflavones, gallotannins, etc.) Degradable tanyun, flavonoids, their derivatives and tea catechins and other polyphenols derived from other plants), carotenoids (lycopene, fastaxanthin, zeaxanthin, rutin, etc.), saponins (ginsesanoide, glycyrrhizic acid, etc.) Xanthine derivatives (caffe
  • a seasoning may be added.
  • the seasoning include sweeteners such as granulated sugar, honey, and sorbit, acidulants such as alcohol, citrate, malic acid, and tartaric acid, and flavors.
  • sweeteners such as granulated sugar, honey, and sorbit
  • acidulants such as alcohol, citrate, malic acid, and tartaric acid, and flavors.
  • components that can promote sugar metabolism or sugar It is preferable to mix a component capable of suppressing absorption.
  • components necessary for useful bacteria such as thiamines, pyridoxines, amino acids (isoleucine, leucine, ⁇ ⁇ phosphorus, serine, proline, darlicin, alanine, threonine, etc.), citrate, malic acid, etc. You may mix. Further, these are made into capsules such as hard capsules and soft capsules, tablets or pills, powders, granules, tea bags and the like. Furthermore, it can be in the form of cheese, margarine, yognoreto or milk. These can be taken as is, or with water, hot water, juice, etc. or leaching the ingredients, depending on their shape or preference.
  • intestinal flora improving agent can also be used as a health drink.
  • beverages containing intestinal flora improving agents for example, plant fermented juice, vegetable juice
  • an intestinal flora improving agent in (for example, carrot juice), plant extract, fruit juice, etc.
  • a beverage with high functionality or nutritional value can be obtained.
  • oligosaccharide fiber to dietary fiber, it is possible to obtain a more excellent intestinal flora improving effect.
  • sweeteners such as khaj monosaccharide, honey, and sorbit
  • sour agents such as alcohol, citrate, malic acid, and tartaric acid, fragrances, and pigments, and adjust them to your taste.
  • an intestinal flora-improving agent may be mixed with agar to make jelly.
  • an enterococcal flora-improving agent with vegetable juice to make a sherbet, frozen chord or ice cream.
  • Pine bark extract obtained from pine bark using water and ethanol (trade name: Flavangenol, Toyo Shinyaku Co., Ltd.) lg and powder obtained by coating lactic acid bacteria (Streptococcus faecalis) 1 g (viable count 5 XI 0 1 pcs., Cell Biotech), lactulose 18 g, indigestible dextrin 30 g, reduced malt cake 30 g and trehalose 20 g Was prepared. Then, 1 gram of food 1 was packaged.
  • lactic acid bacteria Streptococcus faecalis
  • 1 g viable count 5 XI 0 1 pcs., Cell Biotech
  • lactulose 18 g indigestible dextrin 30 g
  • reduced malt cake 30 g and trehalose 20 g was prepared. Then, 1 gram of food 1 was packaged.
  • Food 2 was prepared by mixing each powder in the same manner as in Preparation Example 1 except that the pine bark extract was not mixed. Then, 1 g of food 2 was packaged.
  • DNA present in the stool was extracted using “Sto o l Mini Ni Kit” (Qiagen).
  • the extracted DNA by mixing the extract containing (0.99 ng measured at OD 280 nm value calculated) and the 200 Myumyu primer 0. 5 mu L of purified water 23 mu, further, PCR Beads (Falumasia Biotech) was added to prepare the sample. Primers were added to amplify the DNA of specific useful bacteria. In other words, for Bifidopactrium 'addresses DNA, add DN A shown in SEQ ID NO: 1 and SEQ ID NO: 2, and for Bacillus coagulans DN A, add DN A of SEQ ID NO: 3 and SEQ ID NO: 4, respectively. I made it wide.
  • PCR conditions are as follows: for bifactacterium adrescens, heat at 94 for 2 minutes, then reaction at 94 for 20 seconds, 45 for 20 seconds, and 72 for 1 minute. The cycle was set to repeat.
  • each PCR amplification product was subjected to electrophoresis using a 1% agarose gel prepared by diluting with TBE buffer containing tris, boric acid, and EDTA, and electrophoresis was performed for 30 minutes.
  • a molecular weight marker “On e S tep L a d d e r 100 (Tsubbon Gene)” was used.
  • the DNA panda in the agarose gel is stained with ethidium promide, and the luminescence intensity of the panda of a given molecular weight is measured using an image analyzer (Tyhoon: Amersham Biotech Co., Ltd.). Digitized.
  • the Bifidobacterium and addressense DNAs are 279 bp, and the Bacillus coagulans DNA is 269 bp.
  • the group that took food 1 had about 2 to 2.6-fold increase in the gene of Bifidopacterum auretsusenopi bacillus coagulance, a useful bacterium, compared to before consumption. .
  • the amount of Bifidopacterium 'adresense's Bacillus coagulans gene which is a useful bacterium, is increased in the group ingested food 1 than in the group ingested food 2. That is, the food containing the intestinal flora-improving agent of the present invention and the intestinal flora-improving agent of the present invention increases useful bacteria in the intestine, or the activity of useful bacteria in the intestine. It can be seen that this is promoting
  • Preparations 1 and 4 were prepared using the pine bark extract, indigestible dextrin, reduced maltose, trehalose, and galatato-oligosaccharide used in Preparation Example 1 in the amounts shown in Table 2 below. It was prepared in the same manner as above. Table 2
  • an agent containing pine bark extract as an active ingredient can be applied not only as an intestinal flora improving agent, but also as an intestinal environment improving agent and constipation improving agent. It is also expected to be effective in suppressing harmful enzymes, preventing lifestyle-related diseases, and improving the allergies.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Agent pour améliorer la flore intestinale bactérienne comprenant un extrait d’écorce d’arbres en tant qu’ingrédient actif ; et une nourriture comprenant un extrait d’écorce d’arbres et au moins un membre choisi parmi le groupe constitué par un oligosaccharide, la bactérie de bacillius bifidus et la bactérie de lactobacillus. Cet agent pour améliorer la flore intestinale et la nourriture sont capables d’augmenter la quantité de bactéries utiles vivant dans les intestins pour exercer de cette façon un effet satisfaisant en vue de l’amélioration de l’environnement intestinal.
PCT/JP2005/004742 2004-06-03 2005-03-10 Agent pour améliorer la flore intestinale bactérienne Ceased WO2005117926A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-165353 2004-06-03
JP2004165353A JP2007308373A (ja) 2004-06-03 2004-06-03 腸内菌叢改善剤

Publications (1)

Publication Number Publication Date
WO2005117926A1 true WO2005117926A1 (fr) 2005-12-15

Family

ID=35462728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/004742 Ceased WO2005117926A1 (fr) 2004-06-03 2005-03-10 Agent pour améliorer la flore intestinale bactérienne

Country Status (2)

Country Link
JP (1) JP2007308373A (fr)
WO (1) WO2005117926A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009051753A1 (fr) 2007-10-16 2009-04-23 Ganeden Biotech, Inc. Compositions de boisson
US8697055B2 (en) 1998-08-24 2014-04-15 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria
US9446111B2 (en) 2009-04-29 2016-09-20 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
US9622502B2 (en) 2008-10-16 2017-04-18 Ganeden Biotech, Inc. Probiotic Bacillus pasta compositions
CN107714741A (zh) * 2017-09-12 2018-02-23 安徽荷金来农业发展股份有限公司 一种肉牛瘤胃积食的防治方法
US10111916B2 (en) 2003-12-05 2018-10-30 Ganeden Biotech, Inc. Compositions comprising Bacillus coagulans spores and whey
US10383342B2 (en) 2007-08-29 2019-08-20 Ganeden Biotech, Inc. Baked goods
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
CN114532540A (zh) * 2022-02-21 2022-05-27 江南大学 麦芽五糖基海藻糖及其微球在调节肠道菌群中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009183257A (ja) * 2008-02-08 2009-08-20 Toyo Shinyaku Co Ltd 食品の風味を改善する方法及び風味が改善された食品
JP6333509B2 (ja) * 2012-06-22 2018-05-30 雪印メグミルク株式会社 還元された桂皮酸類縁化合物含有画分の製造方法
JP2014079208A (ja) * 2012-10-17 2014-05-08 Ryozo Saito 腸内環境及び腸管バリア改善サプリメント
JP2017001966A (ja) * 2015-06-05 2017-01-05 株式会社東洋新薬 血中中性脂肪上昇抑制組成物
JP2020196770A (ja) * 2020-09-16 2020-12-10 株式会社東洋新薬 血流改善剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002275076A (ja) * 2001-03-15 2002-09-25 Toyo Shinyaku:Kk 血糖上昇抑制剤および健康食品
JP2003284525A (ja) * 2001-12-19 2003-10-07 Hayashibara Biochem Lab Inc ポリフェノールの水に対する溶解性の改善方法ならびにポリフェノール高含有水溶液
JP2003325136A (ja) * 2002-05-08 2003-11-18 Toyo Shinyaku:Kk 関節炎改善用食品
JP2003334022A (ja) * 2002-05-17 2003-11-25 Toyo Shinyaku:Kk 持久力向上用食品組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002275076A (ja) * 2001-03-15 2002-09-25 Toyo Shinyaku:Kk 血糖上昇抑制剤および健康食品
JP2003284525A (ja) * 2001-12-19 2003-10-07 Hayashibara Biochem Lab Inc ポリフェノールの水に対する溶解性の改善方法ならびにポリフェノール高含有水溶液
JP2003325136A (ja) * 2002-05-08 2003-11-18 Toyo Shinyaku:Kk 関節炎改善用食品
JP2003334022A (ja) * 2002-05-17 2003-11-25 Toyo Shinyaku:Kk 持久力向上用食品組成物

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697055B2 (en) 1998-08-24 2014-04-15 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria
US10111916B2 (en) 2003-12-05 2018-10-30 Ganeden Biotech, Inc. Compositions comprising Bacillus coagulans spores and whey
US10383342B2 (en) 2007-08-29 2019-08-20 Ganeden Biotech, Inc. Baked goods
JP2011500055A (ja) * 2007-10-16 2011-01-06 ガネーデン バイオテック インコーポレイテッド 飲料組成物
JP2013172746A (ja) * 2007-10-16 2013-09-05 Ganeden Biotech Inc 飲料組成物
EP2638807A1 (fr) * 2007-10-16 2013-09-18 Ganeden Biotech, Inc. Compositions de boisson
AU2008311932B2 (en) * 2007-10-16 2014-05-29 Ganeden Biotech, Inc. Beverage compositions
JP2016082977A (ja) * 2007-10-16 2016-05-19 ガネーデン バイオテック インコーポレイテッド 飲料組成物
WO2009051753A1 (fr) 2007-10-16 2009-04-23 Ganeden Biotech, Inc. Compositions de boisson
US9622502B2 (en) 2008-10-16 2017-04-18 Ganeden Biotech, Inc. Probiotic Bacillus pasta compositions
US10321704B2 (en) 2008-10-16 2019-06-18 Ganeden Biotech, Inc. Probiotic grain-based compositions
US11419355B2 (en) 2008-10-16 2022-08-23 Ganeden Biotech, Inc. Probiotic grain-based compositions
US9757442B2 (en) 2009-04-29 2017-09-12 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
US9446111B2 (en) 2009-04-29 2016-09-20 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
US11351206B2 (en) 2011-03-31 2022-06-07 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
CN107714741A (zh) * 2017-09-12 2018-02-23 安徽荷金来农业发展股份有限公司 一种肉牛瘤胃积食的防治方法
CN114532540A (zh) * 2022-02-21 2022-05-27 江南大学 麦芽五糖基海藻糖及其微球在调节肠道菌群中的应用

Also Published As

Publication number Publication date
JP2007308373A (ja) 2007-11-29

Similar Documents

Publication Publication Date Title
US8257761B2 (en) Polyphenol-containing products
WO2005117926A1 (fr) Agent pour améliorer la flore intestinale bactérienne
JP5270680B2 (ja) 葉酸が混入された大豆発酵高分子物質及びこれを含む組成物
KR101487431B1 (ko) 식물성 뮤신 및 수용성 식이 섬유소를 이용한 마이크로 코팅 생균제의 제조 방법
JP6458059B2 (ja) 決明子乳酸菌発酵物を有効成分とする便秘改善、治療又は予防用組成物及びその製造方法
JP4624742B2 (ja) シソの葉から得られる発酵物
TW201034584A (en) Process for producing γ-aminobutyric acid-rich material
KR102230517B1 (ko) 충치 억제 활성을 갖는 락토바실러스 살리바리우스를 포함하는 조성물
JP2010100663A (ja) タマネギ発酵物を含有する酵素阻害剤
JP2009215275A (ja) サラシア属植物を含有する経口用組成物
KR100865075B1 (ko) 장내 정착성이 우수한 신규 락토바실러스속 ｓｍ1 균주 및이들이 생산하는 생균제
KR102042151B1 (ko) 고춧잎 추출물을 포함하는 장내 균총 개선용 조성물
JP2003339353A (ja) 美容食品
JP2006075083A (ja) ゴーヤから得られる発酵物
CN114989258B (zh) 植物提取组合物在制备治疗便秘、减肥产品上的应用
JP2010254594A (ja) 腸内バクテロイデス増殖促進剤
KR102167812B1 (ko) 장건강 및 장개선 효능을 가지는 수수 및 팥 발효물 및 이의 제조방법
KR102133473B1 (ko) 고구마 줄기를 포함하는 장내 미생물 개선용 조성물
KR102048434B1 (ko) 무청 고분자 분획물을 포함하는 장내 균총 개선용 조성물
JP4647933B2 (ja) 整腸作用を有する組成物
KR100711930B1 (ko) 유산균의 안정화 및 유산균 증식효과를 갖는 인삼 다당체조성물
KR102210092B1 (ko) 충치 억제 활성을 갖는 락토바실러스 루테리 mg505 를 포함하는 조성물
KR101506995B1 (ko) 오리나무 수피 추출물 및 유산균을 포함하는 항우식성 조성물
KR20200075724A (ko) 무청 추출물을 포함하는 장내 균총 개선용 조성물
KR102855857B1 (ko) 신규 비피도박테리움 롱검 아종 인판티스 균주 및 이의 용도

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP